Ceftizoxime sodium is a semisynthetic, broad-spectrum, third-generation cephalosporin antibiotic. It is the sodium salt of ceftizoxime, which is structurally characterized by a β-lactam ring fused to a dihydrothiazine ring, with an aminothiazole oxime side chain at the 7-position. This specific structure confers stability against many β-lactamases. Its primary application is as an active pharmaceutical ingredient (API) for the treatment of various bacterial infections. It exhibits potent activity against a wide range of Gram-positive and Gram-negative bacteria, including *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Escherichia coli*, *Klebsiella pneumoniae*, and *Haemophilus influenzae*. It is commonly used in clinical settings for serious infections such as pneumonia, urinary tract infections, intra-abdominal infections, and septicemia. Ceftizoxime sodium is typically administered via intravenous or intramuscular injection. As with other cephalosporins, potential side effects include gastrointestinal disturbances, allergic reactions, and transient elevations in liver enzymes. It is an important therapeutic agent in the arsenal against resistant bacterial pathogens.